Alnylam Pharma (ALNY) Stock Buy Rating Kept at BMO Capital; The Price Objective is Set to $160.0; Tortoise Capital Advisors Boosted By $535.57 Million Its Oneok New (OKE) Holding

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals has $220 highest and $34 lowest target. $121.29’s average target is 4.27% above currents $116.32 stock price. Alnylam Pharmaceuticals had 93 analyst reports since August 7, 2015 according to SRatingsIntel. Chardan Capital Markets maintained the stock with “Buy” rating in Thursday, October 6 report. On Tuesday, May 3 the stock rating was maintained by Leerink Swann with “Outperform”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Sell” rating by Nomura on Friday, September 15. The firm has “Buy” rating given on Wednesday, November 16 by Needham. Piper Jaffray maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, December 15. Piper Jaffray has “Buy” rating and $182.0 target. The rating was maintained by Leerink Swann on Thursday, September 21 with “Market Perform”. The rating was upgraded by Goldman Sachs on Monday, October 2 to “Buy”. On Monday, September 25 the stock rating was maintained by Jefferies with “Buy”. As per Thursday, September 7, the company rating was maintained by Piper Jaffray. The firm earned “Buy” rating on Monday, June 26 by BMO Capital Markets.

Tortoise Capital Advisors Llc increased Oneok Inc New (OKE) stake by 269.66% reported in 2017Q3 SEC filing. Tortoise Capital Advisors Llc acquired 9.74 million shares as Oneok Inc New (OKE)’s stock declined 4.12%. The Tortoise Capital Advisors Llc holds 13.35 million shares with $739.66M value, up from 3.61 million last quarter. Oneok Inc New now has $22.33B valuation. The stock decreased 3.85% or $2.18 during the last trading session, reaching $54.4. About 2.72 million shares traded. ONEOK, Inc. (NYSE:OKE) has risen 23.81% since February 9, 2017 and is uptrending. It has outperformed by 7.11% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.40 EPS, down 6.06% or $0.08 from last year’s $-1.32 per share. After $-1.34 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 4.48% negative EPS growth.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $11.54 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Since September 20, 2017, it had 0 buys, and 3 selling transactions for $23.18 million activity. $10.66 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by Greene Barry E. Mason Michael sold $4.84M worth of stock or 36,745 shares.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.60, from 1.52 in 2017Q2. It worsened, as 30 investors sold Alnylam Pharmaceuticals, Inc. shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. Moreover, Bnp Paribas Arbitrage has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). University Of Notre Dame Du Lac has invested 1.04% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Orbimed Advsr Ltd Liability Company owns 1.22% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1.08 million shares. Glenmede Na holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 175 shares. Hall Laurie J Trustee has 3,800 shares. State Board Of Administration Of Florida Retirement Sys reported 108,948 shares stake. Driehaus Cap Mgmt Limited Liability Company has invested 0.05% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Kornitzer Capital Mgmt Inc Ks owns 162,835 shares or 0.33% of their US portfolio. Capital World Investors invested in 137,700 shares. Schwab Charles Inv Mgmt Incorporated has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Bridger Mgmt invested in 383,933 shares. Royal Savings Bank Of Canada stated it has 1,763 shares or 0% of all its holdings. Virginia-based Quantitative Inv Limited Liability Co has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Frontier Mgmt Communications Limited Liability Company holds 0.07% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 84,501 shares. Moreover, Great West Life Assurance Can has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 8,904 shares.

The stock decreased 4.73% or $5.77 during the last trading session, reaching $116.32. About 978,263 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since February 9, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Among 19 analysts covering ONEOK (NYSE:OKE), 8 have Buy rating, 0 Sell and 11 Hold. Therefore 42% are positive. ONEOK has $66.0 highest and $24 lowest target. $54.13’s average target is -0.50% below currents $54.4 stock price. ONEOK had 66 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was downgraded by Citigroup to “Neutral” on Wednesday, January 25. BMO Capital Markets maintained the stock with “Buy” rating in Monday, January 15 report. On Monday, August 14 the stock rating was maintained by Stifel Nicolaus with “Hold”. The rating was downgraded by Oppenheimer on Friday, January 22 to “Perform”. As per Thursday, October 26, the company rating was maintained by Robert W. Baird. The stock of ONEOK, Inc. (NYSE:OKE) has “Hold” rating given on Friday, June 17 by Argus Research. The rating was upgraded by Argus Research to “Buy” on Wednesday, June 21. The stock has “Overweight” rating by Barclays Capital on Wednesday, January 17. RBC Capital Markets maintained the shares of OKE in report on Monday, May 15 with “Hold” rating. Jefferies downgraded ONEOK, Inc. (NYSE:OKE) rating on Wednesday, June 8. Jefferies has “Hold” rating and $42 target.

Tortoise Capital Advisors Llc decreased Dominion Energy Midstrm Prtn (NYSE:DM) stake by 497,583 shares to 6.45 million valued at $205.16 million in 2017Q3. It also reduced Pioneer Nat Res Co (NYSE:PXD) stake by 26,918 shares and now owns 182,480 shares. Noble Midstream Partners Lp was reduced too.